Vertex Pharmaceuticals (VRTX) Current Assets (2009 - 2026)

Vertex Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $11.7 billion for Q1 2026.

• In Q1 2026, Current Assets rose 17.2% year-over-year to $11.7 billion; the TTM figure through Mar 2026 stood at $11.7 billion (up 17.2% YoY), while the FY2025 annual figure was $11.2 billion, up 16.72% from the prior year.
• Current Assets for Q1 2026 stood at $11.7 billion, up from $11.2 billion in the prior quarter.
• The five-year high for Current Assets was $14.7 billion in Q3 2023, with the low at $8.9 billion in Q2 2024.
• The 5-year median for Current Assets is $11.5 billion (2022), against an average of $11.7 billion.
• The sharpest annual moves came in 2022 and 2024: Current Assets surged 38.62% in 2022, then tumbled 35.55% in 2024.
• Vertex Pharmaceuticals' Current Assets stood at $13.2 billion in 2022, then climbed by 6.87% to $14.1 billion in 2023, then slumped by 32.15% to $9.6 billion in 2024, then rose by 16.72% to $11.2 billion in 2025, then rose by 4.73% to $11.7 billion in 2026.
• Business Quant data shows VRTX's Current Assets at $11.7 billion in Q1 2026, $11.2 billion in Q4 2025, and $10.6 billion in Q3 2025.